Hutchmed China(HCM.US)

Event Tracking

Jan9

HUTCHMED stock price falls below 200-day moving average

08:59

Jan7

Hopewell sovleplenib Phase III Trial Results Positive

00:00

Jan5

HUTCHMED Initiates Phase III Study for Pancreatic Cancer Treatment

00:43

Hopson Medical Launches Phase III Clinical Trial for Suralivimab and Camrelizumab Combination Therapy for Metastatic Pancreatic Cancer

00:00

Dec30

Hopewell Healthcare's Savolitinib New Drug Application Accepted by China's National Drug Regulatory Authority

10:20

Chi-Med's MET inhibitor savolitinib NDA accepted and granted priority review by NMPA

10:00

Schedules & Filings

Schedules

Filings

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 138.84 M, Net Income 227.48 M, EPS 1.3

Mar19

Earning Release(EST)

FY2024 Q4 Earning Release (USD) Revenue 162.26 M, Net Income 5.964 M, EPS 0.025

Jul31

Earning Release(EST)

FY2024 Q2 Earning Release (USD) Revenue 152.84 M, Net Income 12.9 M, EPS 0.075

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change